About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Treatment Interruption of Natalizumab

Treatment Interruption of Natalizumab

NCT01071083·33 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Biogen

With

Elan Pharmaceuticals

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Major criteria include:
A diagnosis of a relapsing form of MS
Treatment with natalizumab according to locally approved prescribing information

The record

StatusCompleted

PhasePhase 2

Taking part175

StartedMar 2010

UpdatedSep 19, 2013

Conditions

Relapsing Remitting Multiple Sclerosis

Where33

Research Site
Cullman, Alabama, United States
Research Site
San Francisco, California, United States
Research Site
Fort Collins, Colorado, United States